Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness: ...

FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.

Tradipitant could become the first new pharmacologic treatment for motion sickness in over 40 years.

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on ...

When you buy through links on our articles, Future and its syndication partners may earn a commission.

The film, Papa (爸爸) emerged as the biggest winner with five awards.The ceremony also marked the debut unveiling of the Golden ...

Some 800,000 dried plant specimens from the 150-year-old Singapore Herbarium are being digitised using Picturae’s conveyor belt imaging system. Photojournalist Shintaro Tay takes a behind-the-scenes ...

Kewaunee Scientific Corporation , a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, today announced its successful debt ...

Wagholm Farms in New Hamburg, Ontario, was among the first to show how a tie stall barn can successfully make the leap to ...

The FDA agreed with Vanda's position that motion sickness is an acute, self-limiting physiologic response rather than a chronic or chronic-intermittent condition. The Agency there ...

Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has ...

Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for high unmet medical needs globally, with a market cap of approximately $303.76 million ...